Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on global phase 3 program in children demonstrating Dupixent significantly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback